Current Urology Reports

, Volume 6, Issue 1, pp 29–34 | Cite as

Update on kidney transplantation for the urologist

  • H. Albin Gritsch


The incidence of end-stage renal disease (ESRD) in the United States is increasing dramatically and renal transplantation is the best treatment for many of these patients. The results of kidney transplantation also have improved. This has resulted in a significant demand for organs that is not met by the current supply of deceased donors. There now are more living kidney donors than cadaveric donors because the results of living donor renal transplantation are superior and the prolonged wait for a cadaveric kidney transplant can be avoided. Therefore, urologists will have increasing exposure to patients with ESRD and those with renal transplantation.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    United States Renal Data System 2003 Annual Data Report. Accessed September 22, 2004. This Internet site is updated annually and includes tables that are easily understood and graphs that clearly show the impact of ESRD.Google Scholar
  2. 2.
    Gaston RS, Danovitch GM, Adams PL, et al.: The report of a national conference on the wait list for kidney transplantation. Am J Transplant 2003, 3:775–785.PubMedCrossRefGoogle Scholar
  3. 3.
    Wynn JJ, Distant DA, Pirsch JD, et al.: Kidney and pancreas transplantation. Am J Transplant 2004, 4(suppl 9):72–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Schnitzler MA, Whiting JF, Brennan DC, et al.: The expanded criteria donor dilemma in cadaveric renal transplantation. Transplantation 2003, 75:1940–1945.PubMedCrossRefGoogle Scholar
  5. 5.
    Wijdicks EF: The neurologist and Harvard criteria for brain death. Neurology 2003, 61:970–976.PubMedGoogle Scholar
  6. 6.
    Organ Procurement and Transplantation/Scientific Registry of Transplant Recipients 2003 Annual Report. Accessed September 22, 2004. This Internet site is updated continuously with organ donation and transplant statistics. The annual report provides national and center specific statistics.Google Scholar
  7. 7.
    Fabrizi F, Lunghi G, Martin P: Hepatitis B virus infection in hemodialysis: recent discoveries. J Nephrol 2002, 15:463–468.PubMedGoogle Scholar
  8. 8.
    Batty DS, Swanson SJ, Kirk AD, et al.: Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant 2001, 1:179–184.PubMedGoogle Scholar
  9. 9.
    Natov SN, Pereira BJ: Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (Part 1: hepatitis B virus). Transpl Infect Dis 2002, 4:117–123.PubMedCrossRefGoogle Scholar
  10. 10.
    Abbott KC, Bucci JR, Matsumoto CS, et al.: Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003, 14:2908–2918.PubMedCrossRefGoogle Scholar
  11. 11.
    Schulam PG, Kavoussi LR, Cheriff AD, et al.: Laparoscopic live donor nephrectomy: the initial 3 cases. J Urol 1996, 155:1857–1859.PubMedCrossRefGoogle Scholar
  12. 12.
    Cecka JM: The UNOS Renal Transplant Registry. Clin Transpl 2002, 1–20.Google Scholar
  13. 13.
    Jacobs SC, Cho E, Foster C, et al.: Laparoscopic donor nephrectomy: the University of Maryland 6-year experience. J Urol 2004, 171:47–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Jordan SC, Vo A, Bunnapradist S, et al.: Intravenous immune globulin treatment inhibits cross-match positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003, 76:631–636.PubMedCrossRefGoogle Scholar
  15. 15.
    Zachary AA, Montgomery RA, Ratner LE, et al.: Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003, 76:1519–1525.PubMedCrossRefGoogle Scholar
  16. 16.
    Steinman TI, Becker BN, Frost AE, et al.: Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 2001, 71:1189–1204.PubMedCrossRefGoogle Scholar
  17. 17.
    Danovitch GM, Hariharan S, Pirsch J, et al.: Management of the waiting list of cadaveric kidney transplants: report of a survey and recommendations by the Clinical Practice Guidelines Committee of the American Society of Transplantation. J Am Soc Nephrol 2001, 13:528–535.Google Scholar
  18. 18.
    Scher LA, Katzman HE: Alternative graft materials for hemodialysis access. Semin Vasc Surg 2004, 17:19–24.PubMedCrossRefGoogle Scholar
  19. 19.
    Meier-Kriesche HU, Kaplan B: Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation 2002, 74:1377–1381.PubMedCrossRefGoogle Scholar
  20. 20.
    Danovitch GM: Handbook of Kidney Transplantation. Philadelphia: Lippincott Williams & Wilkins; 2004. This concise handbook provides current information on all aspects of renal transplantation. The chapter organization quickly answers questions regarding the evaluation and management of renal transplant recipients.Google Scholar
  21. 21.
    Fritsche L, Budde K, Dragun D, et al.: Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant 2004, 4:130–131.PubMedCrossRefGoogle Scholar
  22. 22.
    Kaczmarek I, Groetzner J, Adamidis I, et al.: Sirolimus impairs gonadal function in heart transplant recipients. Am J Transplant 2004, 4:1084–1088.PubMedCrossRefGoogle Scholar
  23. 23.
    Feucht HE, Felber E, Gokel MJ, et al.: Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991, 86:464–470.PubMedCrossRefGoogle Scholar
  24. 24.
    Collins AB, Schneeberger EE, Pascual MA, et al.: Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999, 10:2208–2214.PubMedGoogle Scholar
  25. 25.
    Gloor JM, DeGoey S, Ploeger N, et al.: Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004, 78:221–227.PubMedCrossRefGoogle Scholar
  26. 26.
    Jin YP, Fishbein MC, Said JW, et al.: Anti-HLA class I antibodymediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol 2004, 65:291–302.PubMedCrossRefGoogle Scholar
  27. 27.
    Danovitch GM: How should the immunosuppressive regimen be managed in patients with established chronic allograft failure? Kidney Int Suppl 2002, 68–72.Google Scholar
  28. 28.
    Kasiske BL, Snyder JJ, Gilbertson DT, Wang C: Cancer after kidney transplantation in the United States. Am J Transplant 2004, 4:905–913. This manuscript clearly demonstrates the effects of immunosuppression on the incidence of urologic malignancy.PubMedCrossRefGoogle Scholar
  29. 29.
    Tebyani N, Gritsch HA: Renal cell carcinoma in dialysis and transplantation. In Renal and Adrenal Tumors. Edited by Belldegrun A, Ritchie AW, Figlin RA, et al. New York; Oxford University Press; 2003:74.Google Scholar
  30. 30.
    Pirsch JD, Sollinger HW, Smith CV: Kidney and pancreas transplantation in diabetic patients. In Handbook of Kidney Transplantation. Edited by Danovitch GM. Philadelphia: Lippincott Williams & Wilkins; 2004:390.Google Scholar
  31. 31.
    Shapiro AM, Lakey JR, Ryan EA, et al.: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000, 343:230–238.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • H. Albin Gritsch
    • 1
  1. 1.Department of Urology, David Geffen School of MedicineUniversity of California, Los AngelesLos AngelesUSA

Personalised recommendations